LLY

SVB Securities analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY - Research Report) on November 21. The company's shares closed yesterday at $360.88.Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Gilead Sciences, and Pfizer. According to TipRanks, Risinger has an average return of 13.1% and a 72.34% success rate on recommended stocks. Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $382.71, which is a 6.05% upside from current levels. In a report released yesterday, Berenberg Bank also maintained a Buy rating on the stock with a $375.
https://www.tipranks.com/news/blurbs/svb-securities-sticks-to-its-buy-rating-for-eli-lilly-co-lly-2?utm_source=advfn.com&utm_medium=referral